# CROWN BIOSCIENCE

Lead Identification Screening Services in 3D

Ensure lead identification success with high content analysis

When 3D models and high content collide, they craft a formula for high throughput success. Empower your lead identification search with targeted statistical analysis that moves beyond standard  $IC_{50}$  readouts to structural investigations of your candidates. Test your hypothesis or test the impact of compounds in more complex systems.

#### 3D Spheroid and Organoid Models

#### Different model options available

Take advantage of tumor organoids developed using HUB protocols that are genetically and phenotypically stable and readily scaled up for HTS platforms





eroid Organ

- Samples from both healthy and diseased tissue
- Low batch-to-batch variation
- Growth kinetics and performance consistent across several passages
- Available for repeat studies

#### **Tailor-Made Assay Setups**

#### To enable evaluation of a wide variety of readouts

- Large-scale screens run in a 384-well format
- Perform rapid screening of large numbers of organoid models, single compounds, and combination regimens
- Mark mode of action and off-target effects
- Available assays include tumor cytotoxicity, cell killing, target expression, antibody binding, immune validation, invasion and differentiation

## Beyond High Throughput Screening (HTS) with High Content Services

#### For screens that are accurate as well as clinically representative

With multiparameter image processing and visualization tools, HCI-based HTS can test single agents, compound libraries, dose ranges, and combinations



- Extricate compounds that induce cell cycle arrest, apoptosis, and necrosis
- View the effect of leads on parameters such as organoid size and shape
- Measure activity, binding, toxicity, and synergy with fast readouts of organoid growth/killing
- View from all angles with 3D imaging, CTG, 2D Imaging/IF, 2D Imaging/fluorescent probe, plate-reader, FACS, and sample collection

#### Matched PDX/PDXO Models

### To make informed transitions from early lead series forward to *in vivo* testing

Already established PDX tumors allow for matched *in vitro/ in vivo* models for a more informed transition from early *in vitro* studies to late-phase *in vivo* evaluation.





#### 200+ cell lines

Find your needle in the haystack with functional cell lines that are validated for 3D culture

### 300+ parameters

Catch unexpected drug effects by simultaneously evaluating multiple morphological parameters

#### 500+3D models

Get the highest clinical potential with an expansive living biobank of 3D models Filter out suitable leads with:

- Defined project workflows
- A robust offering of oncology assays
- Reporting of phenotypicbased changes
- Screens performed in highly physiologically relevant systems

#### Get in touch



Sales

**US:** +1 858 622 2900 **UK:** +44 870 166 6234







consultation@crownbio.com www.organoid.crownbio.com

